Novartis AG (NOVN)’s multiple sclerosis pill Gilenya won final approval from England’s health-cost agency for some patients after the company agreed to a discounted price.

The National Institute for Health and Clinical Excellence, or NICE, recommended Gilenya as a treatment option for some adults with relapsing-remitting multiple sclerosis, a form of the disease in which symptoms worsen and improve periodically, it said in a statement today. The decision confirms a preliminary ruling made last month.

Gilenya costs about 19,196 pounds ($30,970). NICE isn’t disclosing the size of the discount that Novartis offered.

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net